Tetraphase Pharmaceutical is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous, or IV, and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Type
Public
HQ
Watertown, US
Founded
2006
Size (employees)
66 (est)
Website
tphase.com
Tetraphase Pharmaceuticals was founded in 2006 and is headquartered in Watertown, US
Report incorrect company information

Tetraphase Pharmaceuticals Office Locations

Tetraphase Pharmaceuticals has an office in Watertown
Watertown, US (HQ)
110 480 Arsenal St
Show all (1)
Report incorrect company information

Tetraphase Pharmaceuticals Financials and Metrics

Tetraphase Pharmaceuticals Financials

Tetraphase Pharmaceuticals's revenue was reported to be $5.15 m in FY, 2016 which is a 56% decrease from the previous period.
USD

Revenue (Q1, 2018)

1.9 m

Net income (Q1, 2018)

(21.6 m)

EBIT (Q1, 2018)

(21.9 m)

Market capitalization (21-May-2018)

183.8 m

Closing share price (21-May-2018)

3.6

Cash (31-Mar-2018)

117.7 m
Tetraphase Pharmaceuticals's current market capitalization is $183.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.3 m9.1 m11.7 m5.1 m

Revenue growth, %

(50%)28%(56%)

EBIT

(112.8 m)(65.8 m)(83 m)(77.8 m)

EBIT margin, %

(617%)(723%)(710%)(1513%)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

2.2 m2.5 m1.3 m2.3 m3 m3.3 m2.9 m2 m1.2 m850 k1.5 m1.6 m4.1 m1.9 m

General and administrative expense

1.9 m3.2 m2.9 m3.1 m4.9 m6.5 m3.9 m5.3 m4.8 m4.9 m5.1 m5.1 m5.6 m5.7 m

R&D expense

10 m12.5 m16.5 m13.2 m18.9 m22.9 m17 m13.5 m13.7 m17.2 m25.9 m28.5 m28.8 m18.1 m

Operating expense total

11.9 m15.7 m19.5 m16.3 m23.8 m29.4 m20.9 m18.8 m18.5 m22 m31.1 m33.6 m34.4 m23.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

102.7 m121 m205.9 m142.1 m

Accounts Receivable

1.7 m3.5 m4.2 m1.8 m

Inventories

1 m2.1 m3.7 m6.6 m

Current Assets

105.4 m126.6 m213.8 m150.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

67.8 m89 m75.4 m56 m260.3 m242.1 m222.5 m189.9 m178.3 m162.1 m128.2 m118.2 m161.4 m117.7 m

Accounts Receivable

2.1 m2 m1.3 m2 m5.5 m3.4 m3.1 m3.8 m3 m745 k1.7 m2.7 m3.6 m3.2 m

Current Assets

72.1 m92.6 m78.5 m60.5 m268.9 m248.4 m228.1 m200.7 m186.5 m169.5 m133.7 m126 m170.4 m127.8 m

PP&E

174 k238 k237 k314 k317 k946 k869 k948 k982 k932 k1.5 m1.5 m1.4 m1.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(29.6 m)(66.7 m)(83.2 m)(77.5 m)

Depreciation and Amortization

129 k124 k193 k282 k

Inventories

(154 k)(1.2 m)(1.5 m)

Accounts Payable

310 k2.2 m(1.2 m)(302 k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(10.1 m)(13.5 m)(18.5 m)(14.2 m)(21 m)(26 m)(18 m)(16.7 m)(17.2 m)(21.1 m)(29.5 m)(21.6 m)

Depreciation and Amortization

116 k

Accounts Payable

6.7 m3.7 m5.6 m5.8 m1.7 m1.5 m2.5 m3.6 m3.6 m(1.7 m)

Cash From Operating Activities

(18.9 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information